With all eyes on Teva ahead of its planned reveal of a fresh strategy under new CEO Richard Francis at an investor day on 18 May, the Israeli firm has delivered first-quarter results that reflected a continued decline in North American generics sales even as the company enjoyed an uptick in other markets.
Meanwhile, Teva also offered an update on US launch plans for its recently-approved long-acting injectable risperidone product, Uzedy (see sidebar),...